My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

84.00 +1.27 (+1.53%)
Streaming Delayed Price Updated: 3:24 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 242,767
Open 83.81
Bid (Size) 83.85 (3)
Ask (Size) 84.14 (1)
Prev. Close 82.73
Today's Range 82.78 - 84.89
52wk Range 42.01 - 117.33
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 Momentum Stock with Competitive Advantages and 2 We Find Risky
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
What Analysts Are Saying About Corcept Therapeutics Stock
Throughout the last three months, 4 analysts have evaluated Corcept Therapeutics (NASDAQ: CORT), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent... 
Via Benzinga

Performance

YTD
+68.1%
+68.1%
1 Month
+20.7%
+20.7%
3 Month
+13.0%
+13.0%
6 Month
+48.2%
+48.2%
1 Year
+97.4%
+97.4%

More News

Read More
Why Are Corcept (CORT) Shares Soaring Today
Via StockStory
Topics Artificial Intelligence
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
From Corcept Therapeutics Incorporated
Via Business Wire
Earnings Scheduled For July 31, 2025
Via Benzinga
Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment
Via StockStory
Topics Artificial Intelligence Intellectual Property
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
3 Cash-Producing Stocks That Concern Us
Via StockStory
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) Embodies the "Affordable Growth" Investment Strategy
Via Chartmill
Corcept Therapeutics Inc (NASDAQ:CORT): A Strong Growth Stock with Solid Fundamentals and Technical Upside
Via Chartmill
3 Cash-Heavy Stocks with Warning Signs
Via StockStory
CORT Q2 Deep Dive: Product Supply Constraints and Pipeline Progress Reshape Outlook
Via StockStory
2 Growth Stocks Set to Flourishand 1 We Avoid
Via StockStory
3 Low-Volatility Stocks That Fall Short
Via StockStory
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
Corcept (NASDAQ:CORT) Misses Q2 Sales Targets
Via StockStory
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
CORCEPT THERAPEUTICS INC (NASDAQ:CORT): A Strong Affordable Growth Pick with Solid Fundamentals
Via Chartmill
What To Expect From Corcept’s (CORT) Q2 Earnings
Via StockStory
Topics Artificial Intelligence
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) – A Strong Growth Stock with Technical Breakout Potential
Via Chartmill
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years
Via Benzinga
agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know
Via StockStory
Topics Lawsuit World Trade
What's Driving the Market Sentiment Around Corcept Therapeutics?
Via Benzinga
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 84.00
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 09/26/25 03:24 PM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 9.74B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 10B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.